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Abstract
Background: The impact of pre-existing diabetes mellitus (DM) on hepatocellular carcinoma (HCC) occurrence and
prognosis is complex and unclear. The aim of this meta-analysis is to evaluate the association between pre-existing diabetes
mellitus and hepatocellular carcinoma occurrence and prognosis.
Methods: We searched PubMed, Embase and the Cochrane Library from their inception to January, 2011 for prospective
epidemiological studies assessing the effect of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence,
mortality outcomes, cancer recurrence, and treatment-related complications. Study-specific risk estimates were combined
by using fixed effect or random effect models.
Results: The database search generated a total of 28 prospective studies that met the inclusion criteria. Among these
studies, 14 reported the risk of HCC incidence and 6 studies reported risk of HCC specific mortality. Six studies provided a
total of 8 results for all-cause mortality in HCC patients. Four studies documented HCC recurrence risks and 2 studies
reported risks for hepatic decomposition occurrence in HCC patients. Meta-analysis indicated that pre-existing diabetes
mellitus (DM) was significantly associated with increased risk of HCC incidence [meta-relative risk (RR)=1.87, 95%
confidence interval (CI): 1.15–2.27] and HCC-specific mortality (meta-RR=1.88, 95%CI: 1.39–2.55) compared with their non-
DM counterparts. HCC patients with pre-existing DM had a 38% increased (95% CI: 1.13–1.48) risk of death from all-causes
and 91% increased (95%CI: 1.41–2.57) risk of hepatic decomposition occurrence compared to those without DM. In DM
patients, the meta-RR for HCC recurrence-free survival was 1.93(95%CI: 1.12–3.33) compared with non-diabetic patients.
Conclusion: The findings from the current meta-analysis suggest that DM may be both associated with elevated risks of
both HCC incidence and mortality. Furthermore, HCC patients with pre-existing diabetes have a poorer prognosis relative to
their non-diabetic counterparts.
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Introduction
Hepatocellular carcinoma (HCC) is the seventh most common
cancer and the fourth leading cause of cancer related death in the
world [1]. More than 80% of HCC cases develop in Asian and
African countries with 55% of the cases reported in China alone
[2], In contrast, the incidence of HCC in the United States and
Western Europe is relatively low. These geographical variations
are in part explained by variations in the prevalence of chronic
infection with hepatitis B virus (HBV) and/or hepatitis C virus
(HCV). Although most HCC cases occur in sub-Saharan Africa
and Eastern Asia, HCC incidence has been declining in some of
these high-rate areas [3–5], partly due to universal vaccination
against hepatitis B virus in the newborns [3,5]. On the contrary,
the incidence trends of HCC have been increasing over the past
three decades in low-endemic areas including the United States,
Canada, and Western Europe. In the United States, for instance,
the age-adjusted incidence of HCC has recently more than tripled,
from 1.6/100,000 in 1975 to 4.9/100,000 in 2005 [6]. The cause
of this increase in low-rate areas is not well understood but may
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hepatitis C viral infection may explain up to 50% of this increase,
HBV infection and alcoholic liver disease (ALD) is unlikely to
explain the remainder [7,8]. In general, more than 25% of HCC
cases do not have any known etiology [9], suggesting other risk
factors, aside from the recognized factors (HBV, HCV and
alcohol), may play an important role in HCC development.
Over the last few decades, the prevalence of diabetes mellitus
(DM) has increased substantially and is highly suspected to be
associated with an increased risk of HCC. Diabetes mellitus is
mainly composed of type I and type II diabetes. Although most
available data do not distinguish between the two types, type II
diabetes makes up the majority of cases worldwide. In the United
States, DM is the sixth leading cause of death and its crude
prevalence in adult U.S. population rose from 5.1% in 1988–1994
to 7.7% in 2005–2006 [10]. Many studies, including several case-
control studies [11–16] and cohort studies [17–25], have reported
a positive association between DM and HCC risk. A possible
explanation for this association relates to the fact that diabetes
often occurs as part of the metabolic syndrome itself characterized
by a group of biochemical abnormalities and associated clinical
conditions which include disturbed glucose and insulin metabolism
resulting in hyperglycemia and hyperinsulinemia, dyslipidemia,
and hypertension. The metabolic derangements associated with
metabolic syndrome (hyperinsulinemia, hyperglycemia, and dysli-
pidemia) can lead to diabetes mellitus and/or atherosclerotic
cardiovascular disease. Moreover, these aforementioned metabolic
abnormalities may contribute to the increasing risk of nonalcoholic
fatty liver disease (NAFLD), including its most severe form,
nonalcoholic steatohepatitis (NASH), and that HCC may be a late
subsequent consequence of cirrhosis caused by NAFLD; however
some studies have refuted this association [26–29].. Additionally,
reverse causality is a major concern for causal inference in these
case-control studies because in some cases diabetes might itself be
a result of cirrhosis.
Diabetes mellitus may be a risk factor for some cancers;
however the impact of pre-existing DM on overall cancer
prognosis, including cancer recurrence, cancer mortality, and
all-cause mortality, remains unclear [30–32]. Although diabetes is
associated with age-adjusted excess mortality, whether the excess
mortality associated with DM in cancer patients is any greater
than the excess mortality observed among diabetic patients
without cancer requires further investigation. Nonetheless, some
studies have reported that pre-existing DM in cancer patients at
the time of diagnosis is associated with increased risk of all-cause
mortality [30,31]. In particular, previous studies have shown a
significant association between DM and cancer prognosis for
specific sites such as breast cancer, prostate cancer, endometrial
cancer, colon, and rectum [21,33–38].
There have been several proposed mechanisms explaining the
association between DM and cancer prognosis. Type II DM and
metabolic syndrome have both been associated with a state of
chronic, low grade inflammation. Inflammatory conditions can
initiate or promote oncogenic transformation. Concurrently,
genetic and epigenetic changes in malignant cells can generate
an inflammatory environment which supports tumor progression
and hepatocellular carcinoma [39–41]. Additionally, DM provides
an environment of hyperinsulinemia and hyperglycemia, both of
which may increase tumor cell proliferation and metastasis
[30,42–43]. Acute exposure to hyperglycemia may increase
endothelial cell permeability due to increased generation of
reactive oxidative species and structural changes in the basement
membrane thereby increasing the likelihood of metastasis [44–46].
Also, insulin or insulin like growth factor levels may promote
cancer cell and tumor growth [37,47–51]. Furthermore, patients
with pre-existing DM often have other diabetes-related comorbid
conditions that may influence clinical decisions and response to
cancer treatment, including poor response, increased risk of
infection and intraoperative morbidity and mortality [36,52–54].
The role of DM on HCC incidence remains controversial and it
is less clear whether pre-existing DM can influence overall
survival, risk of recurrence, and treatment-related complications
in HCC patients. In the limited studies conducted, the impact of
DM on hepatocellular carcinoma has been inconsistent with one
meta-analysis reporting no significant association with prognosis
[31,32]. We therefore conducted a meta-analysis, combining the
results from long-term prospective epidemiological studies, to
investigate: i) the association between pre-existing DM and HCC
incidence, and ii) the possible effect of pre-existing diabetes
mellitus on prognosis in HCC patients.
Methods
Searching
We systematically identified studies through searching EM-
BASE, Medline (PubMed) and the Cochrane Library from their
inception to January 1, 2011 for human, English and Chinese-
language studies on evaluating the effect of pre-existing diabetes
on HCC occurrence and any prognostic outcome in HCC
patients. Our overall search strategy included terms for hepato-
cellular carcinoma (cancer, liver neoplasm, primary liver cancer,
hepatocellular carcinoma), diabetes (metabolic syndrome, diabetes
mellitus, diabetes, hyperglycemia), and study design (cohort
studies, follow-up, prospective studies). Furthermore, the cited
references of retrieved articles were hand-searched to locate the
additional relevant studies.
Selection
Articles were included into the meta-analysis if they: i.) were
prospective studies; ii.) evaluated the association between diabetes
and any HCC prognostic outcome or risk of HCC occurrence; iii.)
contained original data and iv.) reported a risk estimate (i.e.,
hazard ratio or relative risk) regarding pre-existing DM to
subsequent incidence or any prognostic outcome and its 95%
confidence interval (CI) or its standard error (SE). If the
publications were duplicated or shared in more than one study,
either the most recent publication or the publication with
multivariate-adjusted estimates was included.
Data abstraction
Two of the authors (PV and W-SY) independently evaluated the
eligibility of all retrieved studies from the databases and extracted
all the relevant data from each study included using a unified data
form. The extracted information included in the data form were as
follows: study name (together with first author’s name and year of
publication), country, study design (clinic-based or population-
based cohort studies), inclusion for study cohort, sample size
(numbers of pre-existing diabetes and cohort size), range of follow-
up time, statistical adjustments for confounders in analysis and
study results (adjusted RR or HR with their corresponding
95%CIs for HCC occurrence or any HCC prognostic outcome by
diabetes), method of diabetes and outcome ascertainment.
Afterwards, two lists from evaluators were compared and
disagreements were resolved by consensus between the two review
authors.
A 7-point scoring system was created to evaluate study quality.
Studies that confirmed pre-existing DM by medical record or
medication use were assigned 1 point. Studies that used medical
Pre-Existing Diabetes and Liver Cancer Outcome
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that used a death certificate or cancer registry received 1 point.
Allowing for major potential confounders (i.e., HBV, HCV and
alcohol drinking) being controlled in varying degrees across the
included articles, studies adjusting for HBV in an African country
or an Asian country (except for Japan) or HCV in a European
country, USA or Japan received 2 points; those that also adjusted
for one or more of the two remaining major potential confounders
received an additional 1 point. Clinic-based cohort studies with
loss to follow-up of ,5% received 1 point, while population-based
cohort studies with loss to follow-up of ,20% received 1 point.
Studies could receive up to maximum score of 7 points. High
quality studies were defined as a study with a quality score$5
points.
Statistical methods
To fully consider the effect of pre-existing DM in HCC outcome
of interest (occurrence and prognosis), the aim of our analysis was
divided into 5 parts based on different outcomes reported in each
included article. In 28 articles [17–29,55–69], 7 [17–19,21–23,61]
of 12 [17–19,21–23,56,58,61,63,64,68] population-based cohort
studies and 7 [20,24–29] of 16 [20,24–29,55,57,59,60,62,65–
67,69] clinic-based cohort studies reported the risk of pre-existing
DM in HCC occurrence and were included in the first part of
meta-analysis on DM in relations to HCC incidence risk. In the
second part, 6 [56,58,61,63,64,68] population-based cohort
studies that provided data for risk of HCC specific mortality in
subjects with history of diabetes were analyzed. In the third part, 6
[55,60,62,66,67,69] clinic-based cohort studies were summarized
to evaluate the prognostic effect of pre-existing DM on all-cause
mortality in HCC patients. We statistically combined 4
[57,59,67,69] and 2 [62,65] clinic-based cohort studies for the
fourth and fifth part of our investigation to evaluate the association
between the pre-existing DM with HCC patients’ prognosis on
recurrence-free survival (RFS) and cancer treatment-related
hepatic decomposition (HD) occurrence, respectively. To compute
a summary RR with its 95% CI, we used the study-specific
adjusted RR or HR and its 95%CI in all analyses. All RR or HR
extractions were performed separately by PV and W-SY.
Disagreements were resolved by discussion.
In this analysis, we examined possible heterogeneity in results
across studies using the Cochran Q and I
2 statistics [70]. The null
hypothesis that the studies are homogeneous would be rejected if
P-value for heterogeneity is less than 0.10 or I
2$50%. When there
is significant heterogeneity among study results, the random effects
model (DerSimonian and Laird method) [71] was used to calculate
summary estimate assuming that the studies included in the meta-
analysis have the varying effect size across studies. Otherwise, the
summarized estimate was calculated based on the fixed effects
model (the inverse variance method), assuming that the studies
included in the meta-analysis have the same effect size.
There is a tendency on average to produce results that appear
significant, given negative or near neutral results are almost never
published. This is the so-called publication bias and may bias
results of the meta-analysis. In an attempt to evaluate the possible
publication bias, Egger’s test (linear regression method) [72] and
Begg’s test (rank correlation method) [73] were used, and P-
value,0.05 was considered representative of significant statistical
publication bias. If publication bias was identified, the ‘‘trim and
fill’’ method, suggested by Duval and Tweetdie [74], was adopted
to further assess the effect of correcting the publication bias. This
method relies on scrutiny of one side of a funnel plot for
asymmetry assumed due to publication bias and recalculates a
pooled estimate considering the number of studies missing from a
meta-analysis so that the funnel plot is more symmetric. All data
analyses were performed using the R 2.12.1 statistical software
(meta 1.6-1 package) (R Development Core Team, 2010, available
from: www.r-project.org).
Results
Literature search and quality assessment
Figure 1 shows a flow diagram of how we selected relevant
studies. Our systematic literature search yielded a total of 28
articles in the final analysis, comprising 12 population-based
cohort studies and 16 clinic-based cohort studies. Outcomes
reported in each article included HCC occurrence (n=14) [17–
29,61], HCC-specific mortality (n=6) [56,58,61,63,64,68], all-
cause mortality (n=6) [55,60,62,66,67,69], recurrence-free sur-
vival (n=4) [57,59,67,69], and hepatic decomposition as a
Figure 1. Selection of studies in the Meta-analysis.
doi:10.1371/journal.pone.0027326.g001
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between 1998 and 2010, of which 64% (n=18) were published in
2005 or more recent years. The studies were conducted in the
following regions: Japan (n=9) [20,22,23,25,57–59,68,69], China
(n=8) [18,21,26,55,62,65–67],Korea (n=2) [60,61], USA (n=3)
[24,29,63], Europe (n=4) [19,27,28,64], Israel (n=1) [17] and
other regions (n=1) [56]. The cohort ranged in size from 40 [57]
to 1,298,385 [61].The duration of follow-up ranged from 2.78
years [21] to 25 years [64] in population-based cohort studies and
ranged from 18 months [55] to 7 years [8] in clinic-based cohort
studies. Seven studies [18,19,21,26,55,66,68] assessed type II DM
only; and an additional 21 studies did not distinguish between type
I and type II DM. The characteristics of the included studies are
shown in Table S1.
According to our 7-point scoring system, the study-specific
quality scores are summarized in Table 1. Half (n=14) of the
studies were defined as high quality studies (score$5 points), of
which 12 were clinic-based cohort studies and 2 were population-
based prospective studies. Of the 28 studies, 19 [17,18,20,21,24–
27,29,55–57,59,61,62,65–67,69] used medical records or docu-
mented use of diabetic medicine to ascertain DM diagnosis and
the remaining 9 studies used self-reported data or a disease
registry. Medical records were used to ascertain outcomes in 18
[20–25,27–29,55–57,59,62,65–67,69] studies while others used
cancer registry data or death certificate.
Diabetes and HCC incidence
Based on 14 studies, pre-existing DM was associated with an
87% risk increase for HCC incidence (RR=1.87, 95%CI: 1.55–
2.27; shown in Figure 2). Statistically significant heterogeneity was
found among these studies (I
2=70.8%, Q=44.5, df=13,
P,0.0001; Table 2) and thus random effects models were
employed. There was no indication of a publication bias, either
from Egger’s test (P=0.250) or from Begg’s test (P=0.295).
In the subgroup analyses (Table 2), when analyses was restricted
to high quality studies only, we observed 21% reduction in risk
estimate as compared with the overall estimate (RR=1.66,
95%CI: 1.09–2.51; n=7). By study design, we found similar
results for clinic-based cohorts (RR=1.75, 95%CI: 1.10–2.79) and
for population-based cohorts (RR=1.73, 95%CI: 1.61–1.86).
Table 1. Assessment of study quality.
Study Diabetes Outcome Loss to follow-up Major confounders control Quality
ascertainment ascertainment ,20%(PC) ,5%(HC) HBV HCV Alcohol drinking score
Ikeda Y 1998 [69] MR or MU MR - Yes Yes Yes No
Fujino Y 2001 [68] SR DC Unknown - No No Yes 1
Tazawa J 2002 [25] MR or MU MR - Yes No Yes No 6
Poon RTP 2002 [67] MR or MU MR - Yes Yes No Yes 7
Huo TI 2003 [66] MR or MU MR - Yes Yes Yes No 7
Huo TI 2003 [65] MR or MU MR - No Yes No No 5
El-Serag HB 2004 [24] MR MR - Yes No No No 3
Huo TI 2004 [62] MR or MU MR - Yes Yes No No 6
Coughlin SS 2004 [63] MR or SR CR Unknown - No No Yes 1
Batty GD 2004 [64] SR CR Unknown - No No No 1
Jee SH 2005 [61] MR CR Unknown - No No Yes 2
Park SM 2006 [60] MR or SR CR - Yes No No Yes 2
Inoue M 2006 [23] SR MR Yes - No No Yes 3
Khan M 2006 [22] SR CR Unknown - No No Yes 1
Lai MS 2006 [21] MR MR Unknown - Yes Yes Yes 6
Torisu Y 2007 [20] MR MR - No No No Yes 3
Komura T 2007 [59] MR MR - Yes Yes Yes Yes 7
Ioannou GN 2007 [29] MR MR - Yes Yes Yes Yes 7
Kawamura Y 2008 [57] MR MR - No No No Yes 3
Di Costanzo GG 2008 [28] MU or SR MR - Yes No No Yes 5
Veldt BJ 2008 [27] MR or MU MR - Yes No No Yes 6
Oba S 2009 [58] SR CR Unknown - No No Yes 1
Ogunleye AA 2009 [19] DR CR Unknown - No No No 1
Wang CS 2009 [18] MR CR Yes - Yes Yes No 7
Lam EK 2010 [56] MR Unknown Unknown - No No No 1
Chodick G 2010 [17] MR or MU CR No - No No No 2
Hung CH 2010 [26] MR DC - Yes Yes No Yes 6
Huo TI 2010 [55] MR or MU MR - Yes Yes Yes No 7
Abbreviations: CR, cancer registry; DC, death certificate; DR, diabetes registry; HC, hospital-based cohort study; MR, medical record; MU, medication use; PC, population-
based cohort study; SR, self-report.
doi:10.1371/journal.pone.0027326.t001
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studies with (RR=2.05, 95%CI: 1.23–3.42) and without
(RR=1.88, 95%CI: 1.54–2.30) adjustments for major confound-
ing factors.. Analyses stratified by study area showed that DM was
associated with a greater risk of HCC in Japan (RR=2.80,
95%CI: 1.66–4.68; n=4) than in other Asian countries
(RR=1.59, 95%CI: 1.06–2.38; n=4). Analyses confined to
studies using medical records or medication use as a means of
DM ascertainment yielded similar results (RR=1.88, 95%CI:
1.49–2.37; n=10) compared to studies using self-report data or
disease registry to determine DM status (RR=1.90, 95%CI: 1.12–
2.97; n=4). Studies using medical records to ascertain outcome
(RR=1.95, 95%CI: 1.48–2.58; n=10) demonstrated slightly
higher increased risk than studies adopting other methods for
outcome ascertainment (RR=1.83, 95%CI: 1.289–2.61; n=6).
When examining differences over time, we found that studies
published after 2005 had a summary estimate with a meta-RR of
1.85(95%CI: 1.37–2.51), while studies published before 2005 had
a summary estimate with a meta-RR of 2.00(95%CI: 1.50–2.66).
Diabetes and HCC specific mortality
Six population-based prospective studies [56,58,61,63,64,68] on
HCC specific mortality were included and indicated that pre-
existing DM was associated with a 1.88-fold elevated risk (95%CI:
1.39–2.55; shown in Figure 3) of HCC-specific mortality. We
found no statistical evidence of publication bias (Egger’s test:
P=0.371; Begg’s test: P=0.851). The random effect model was
implemented due to substantial heterogeneity in the estimates
across studies (I
2=71.6%, Q=17.6, df=5, P=0.0035). The
meta-RR was 2.18(95%CI: 1.77–2.68) in two studies [63,68] that
controlled for major confounders and 1.76(95%CI: 1.18–2.63) in 4
studies [56,58,61,64] that did not control for major confounders;
Studies published prior to 2005 had a meta-RR of 2.20(95%CI:
1.78–2.70; n=3) while studies published after 2005 had a meta-
RR of 1.70(95%CI: 1.13–2.55). Additionally, studies using
medical records or medication use as DM ascertainment had a
meta-RR of 1.40(95%CI: 1.18–1.66; n=2) whereas studies using
other methods to confirm DM yielded a meta-RR of 2.35(95%CI:
1.83–3.02; n=4).
Figure 2. Summary estimate of relative risk (RR) for HCC incidence in diabetic patients in comparison with non-diabetic patients.
Squares represent study-specific estimates (size of the square reflects the study-specific statistical weight, i.e. inverse of the variance); horizontal lines
represent 95% CIs; diamonds represent summary estimates with corresponding 95% CIs.
doi:10.1371/journal.pone.0027326.g002
Table 2. Meta-analysis for pre-existing diabetes mellitus and
HCC incidence.
No. of Meta-RR Heterogeneity
studies (95%CI) I
2 (%) P-value
Overall 14 1.87(1.55–2.27) 70.8 ,0.0001
Higher quality (score$5) 7 1.66(1.09–2.51) 73.8 0.0008
Study design
Clinic-based cohort 7 1.75(1.10–2.79) 81.7 ,0.0001
Population-based cohort 7 2.04(1.67–2.48) 43.6 0.1005
Major confounders control
Yes 7 2.05(1.23–3.42) 75.1 0.0005
No 7 1.88(1.54–2.30) 70.5 0.0024
Study areas
Japan 4 2.80(1.66–4.68) 53.7 0.0903
Asian countries (except for
Japan)
4 1.59(1.06–2.38) 78.9 0.0026
European Union+USA 5 1.77(1.23–2.57) 68.6 0.0126
Israel 1 2.42(1.00–5.84) - -
Year of publication
#2005 3 2.00(1.50–2.66) 84.7 0.0014
.2005 11 1.85(1.37–2.51) 68.1 0.0005
Diabetes ascertainment
MR or MU 10 1.88(1.49–2.37) 73.3 ,0.0001
Others 4 1.90(1.12–2.97) 71.6 0.0143
Outcome ascertainment
MR 8 1.95(1.48–2.58) 64.4 0.0063
Others 6 1.83(1.28–2.61) 72.2 0.0030
MR, medical record; MU, medication use; Meta-RR, Meta-relative risk.
doi:10.1371/journal.pone.0027326.t002
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Six studies [55,60,62,66,67,69] assessing the association be-
tween DM and all-cause mortality were collapsed to obtain a
meta-RR of 1.38(95%CI: 1.13–1.68)(Figure 4), suggesting a poor
overall survival in HCC patients with pre-existing diabetes
compared with their non-diabetic counterparts. However, large
heterogeneity existed in these studies (I
2=63.9%, Q=19.4, df=7,
P=0.0007); hence the random effect model was adopted. We
observed significant publication bias according to both Egger’s test
(P=0.048) and Begg’s test (P=0.030). The trim and fill method
was used to recalculate the meta-RR thus correcting for the
publication bias. The adjusted risk estimate however could not
reverse this significant positive association (RR=1.22, 95%CI:
1.00–1.49; P=0.0492).
Subgroup analyses confined to high quality studies showed a
strong RR for all-cause mortality in HCC patients (RR=1.49,
95%CI: 1.18–1.87; n=5). When analysis was restricted to HCC
patients who received curative surgery only [62,66,67,69], the
meta-RR was 1.64(95%CI: 1.15–2.33); Studies controlling for
major confounders yielded a RR of 1.49(95%CI: 1.18–1.87;
n=5). Studies using medical records or medication use as diabetes
ascertainment had a meta-RR of 1.49(95%CI: 1.18–1.87; n=5).
In our sensitivity analysis, excluding the estimate by Huo et al
2004(a) [62] resulted in the lowest summary estimate (RR=1.32,
95%CI:1.09–1.61) whereas omission of the study by Park et al [60]
resulted in the highest summary estimate (RR=1.49, 95%CI:
1.18–1.87).
Diabetes and recurrence-free survival in HCC patients
Of the 4 [57,59,67,69] articles that reported pre-existing DM
and recurrence-free survival in HCC patients, our meta-analysis
identified pre-existing DM as a significant predictor for HCC
recurrence (RR=1.93, 95%CI: 1.12–3.33)(Figure 5). We found no
evidence of publication bias with either Egger’s test (P=0.174) or
Begg’s test (P=0.625). Due to substantial heterogeneity across
studies (I
2=70.3%, Q=10.1, df=3, P=0.0177), we used the
random effect model. Sensitivity analysis showed that removing
the study by Poon RTP et al [67] had a minimal effect on the
summary estimate (RR=2.05, 95%CI: 1.56–2.70). When analysis
was restricted to HCC patients receiving curative surgery only, we
found that the recurrence risk in diabetic patients was
1.66(95%CI: 0.96–2.87) compared to non-diabetic patients.
Diabetes and hepatic decomposition as a complication in
HCC patients
We combined 2 studies [62,65] on DM and hepatic decompo-
sition (HD) as a complication in HCC patients. Subjects with
diabetes had a significantly increased risk of HD occurrence,
compared with non-diabetic subjects (RR=1.91, 95%CI: 1.41–
2.57) (shown in Figure 6). We did not detect any significant
Figure 3. Summary estimate of relative risk (RR) for HCC specific mortality in diabetic patients compared with their non-diabetic
counterparts. Squares represent study-specific estimates (size of the square reflects the study-specific statistical weight, i.e. inverse of the variance);
horizontal lines represent 95% CIs; diamonds represent summary estimates with corresponding 95% CIs.
doi:10.1371/journal.pone.0027326.g003
Figure 4. Summary estimate of relative risk (RR) for all-cause mortality in HCC patients with pre-existing diabetes mellitus
compared with their non-diabetic counterparts. Squares represent study-specific estimates (size of the square reflects the study-specific
statistical weight, i.e. inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary estimates with corresponding 95%
CIs.
doi:10.1371/journal.pone.0027326.g004
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ble, given the limited number of studies included.
Discussion
In our meta-analysis of HCC incidence, DM was significantly
associated with an 87% elevated risk of HCC occurrence. This
positive association was not reversed across subgroup analyses,
regardless of study quality, study area, study design, statistical
adjustments, and year of publication (shown in Table 2).
Interestingly, we found a higher liver risk of cancer incidence
associated with DM in Japan (HCV-related HCC area) than in
other Asian countries (HBV-related HCC areas). This geographic
variability may reflect differences in etiology and need to be
further explored. Due to limited information available regarding
effect modification between DM and other important risk factors
in relation to HCC incident risk, we were not able to evaluate the
possible interactions. Moreover, the results of the subgroup
analyses by diabetes and outcome ascertainment were consistent
with the comprehensive meta-analysis, supporting the argument
that self-reported history of diabetes may be reasonably accurate
[68,75,76].
Compared with incidence studies, mortality studies have less
superiority in causal inference, especially in DM and HCC studies.
Given the long latent time period between DM onset and HCC
death, it is impossible that the relatively limited follow-up period is
sufficient to clarify the effects of reverse causality. Furthermore,
this relatively short duration of follow-up might not capture all
mortality from HCC cases with longer survival time. Additionally,
most population-based studies on HCC mortality ascertained
death from HCC based on national vital statistics, where DM
related death or associated death may not always be recorded on
death certificates among cancer cases [77]; hence this approach
seemed to be unreliable. The combined result for HCC specific
mortality of the 6 population-based studies, however, was similar
to that for HCC incidence (HR=1.88, 95%CI: 1.39–2.55). This
close similarity could be explained by long duration of follow-up,
high quality of cancer death registries in the included mortality
studies, and high HCC case-fatality of incident cases. Among those
studies, the follow-up time ranged from 4 years to 25 years where 4
of the 6 studies reported more than 10 years of follow-up
[61,63,64,68]. Subgroup analyses showed that combined estimates
for DM-associated HCC mortality varied across selected strata of
different methodology of diabetes measurement, major confound-
er adjustment, and year of publication. These discrepancies may
be partly due to the small number of studies within each stratum.
Despite the consistent findings from HCC incidence and specific
mortality studies, several issues relating to casual inference on the
association between DM and HCC should be noted. First, although
it is almost certain that the diagnosis of diabetes preceded the
diagnosis ofHCCincohortstudies weanalyzed,the possiblereverse
causality in some studies could not be ruled out because it was
unknown as to whether diabetes preceded the underlying chronic
liver disease, and in some cases diabetes might be caused by these
chronic liver disease. In studies of DM and HCC incidence and
specific mortality, only one [65] excluded patients with known
baseline liver disease from the cohort entry. Second, cohort studies
in the analyses that had a relatively short duration of follow-up and/
or examined younger populations were not well suited to evaluate
the temporality, given the low incident HCC cases or power, and
greater loss to follow-up in these studies. For example, two hospital-
based [27,29] and three population-based [19,21,56] cohort studies
Figure 5. Summary estimate of relative risk (RR) for HCC recurrence-free survival (RFS) in HCC patients with pre-existing diabetes
mellitus in comparison with non-diabetic patients. Squares represent study-specific estimates (size of the square reflects the study-specific
statistical weight, i.e. inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary estimates with corresponding 95%
CIs.
doi:10.1371/journal.pone.0027326.g005
Figure 6. Summary estimate of relative risk (RR) for hepatic decomposition (HD) occurrence in HCC patients with pre-existing
diabetes mellitus in comparison with non-diabetic patients. Squares represent study-specific estimates (size of the square reflects the study-
specific statistical weight, i.e. inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary estimates with corresponding
95% CIs.
doi:10.1371/journal.pone.0027326.g006
Pre-Existing Diabetes and Liver Cancer Outcome
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e27326reported an average follow-up period of no more than 4 years,
however the time of follow-up in other studies was fairly long
(.4years). Third, although most included studies considered major
confounding factors such as HBV and HCV infection, body mass
index, and alcohol drinking, the inability to adjust fully for other
important risk factors, particularly for treatment modalities for
diabetes, could have biased the results. Evidence show that some
medications for diabetes such as metformin [78] can decrease the
risk of cancer, whereas use of exogenous insulin and insulin
secretagogues such as sulfonylureas can increase the risk of cancer
incidence and/or mortality [79,80]. Lastly, the duration of diabetes
at cohort entry is less clear across the studies where only one study
[61] evaluated a duration-response relationship (changes in RR for
HCC according to different durations of diabetes). Consequently,
we failed to evaluate such duration-response trends in our analysis
and thus cannot draw a firm conclusion. Therefore, additional
studies are warranted to better define the onset of diabetes in
relationship to onset of liver disease, and to clarify how any excess
risk conveyed by diabetes is mediated by duration and treatment
modalities of diabetes.
Although reported associations between pre-existing DM and
mortality in patients with cancer have been inconsistent and varied
with site, our results indicate that DM is associated with cancer
prognosis. Having pre-existing DM increased the risk of all-cause
mortality, recurrence after HCC treatment, and hepatic decom-
position. The risk of all-cause mortality increased by 38% in
patients with diabetes compared to those without diabetes. The
magnitude of association only increased when analysis was
restricted to high quality studies (49%) and remained consistent
amongst studies adjusting for major confounders. Although our
results indicate that pre-existing DM portends an elevated all-
cause mortality, it is important to note that these data do not
necessarily suggest a causal relationship. Such elevated risk could
be associated with DM due to increased risk of complications,
morbidity, and mortality associated with diabetes itself. We were
unable to analyze the data further to assess mortality risks
excluding DM-related causes of mortality because most of the
studies involved in the analysis assessed overall survival and all-
cause mortality. Of the six studies analyzed, only one study
confined analysis to cancer related deaths, excluding DM related
causes of death [60], in which the authors found that a positive
association remained between DM and cancer mortality with or
without the inclusion of DM-related deaths. Additionally, poor
prognosis amongst patients with pre-existing DM may be
attributable to a multitude of interactions and factors. These
factors include tumoral factors such as size, extent of liver
damage/cirrhotic factors, tumor recurrence, and DM-associated
factors such as insulin intolerance [62]. One study found that DM
was a poor prognostic indicator of long-term survival in patients
with tumors ,5 cm due to the occurrence of DM-related deaths
[62]. Moreover, most patients with HCC have liver cirrhosis as a
result of long term chronic liver disease. Diabetes may accelerate
mortality by accelerating liver fibrosis, inflammation with
increased inflammatory markers and cytokines resulting in severe
liver failure [81–83] and poor cancer prognosis [39–41]. Also, it is
possible that pre-existing diabetes may potentiate the incidence of
bacterial infections in cirrhotic patients which has been shown to
increase mortality [84]. However, the pathophysiology underlying
cancer prognosis and diabetes remains uncertain and requires
further investigation [32]. It is important to note that our analysis
of hepatic decomposition was limited to few studies and should be
interpreted with caution.
We observed that the risk estimate for HCC specific mortality
was higher than all-cause mortality in patients with pre-existing
diabetes. The elevated mortality risk may be attributed to risk
related to HCC treatment and not necessarily due to the natural
progression of HCC. The etiology of HCC is complex and
influences treatment options available. Although treatment vary
world-wide, first line treatment of early stage HCC is surgical
resection, liver transplantation, and ablative therapies all with
curative intent. For patients with intermediate stage disease with
multifocal lesions and without vascular invasion, the treatment
option is transcatheter arterial chemoembolization (TACE) [85–
87]. Theoretically, liver transplantation is ideal because it removes
the tumor along with accompanying liver disease. Due to a
shortage of donor livers and long waiting times for transplantation,
most clinicians advocate for surgical resection. However, compli-
cations of surgery include decreased liver function, inadequate
liver remnant and hepatic decomposition, all of which may impact
prognosis. Additionally, patients with pre-existing DM and HCC
have liver cirrhosis and thus decreased liver function, and/or other
diabetes related comorbidities making them poor candidates for
surgery or more aggressive treatments resulting in a worse
prognosis [53,86]. Overall, it is difficult to distinguish death from
treatment related liver failure, other treatment related complica-
tions, diabetes or HCC. Analyzing studies across time periods, we
found that mortality risks have declined when comparing current
studies with earlier studies. This slight decline may be a result of
improvements with diabetes management, glucose control [88,89]
as well as HCC classification, identification of therapeutic targets,
and prognosis [85,87,90].
Although diabetes was found to be significantly associated with
recurrence of HCC after treatment, when restricted to patients
who received curative surgery only, the significant association
disappeared. The attenuation of risk may result from inherent
characteristics of surgery. It is commonly accepted that HCC
recurrence is not a result of inadequate resection but more a result
of microscopic tumor foci or due to microscopic dissemination of
neoplastic cells during surgical procedures [87,91,92].
It remains unclear whether diabetes is directly associated with
mortality in cancer patients, if it’s more of an underlying biologic
factor that alters cancer risk such hyperinsulinemia, or whether the
cancer-diabetes association is indirect and a result of common risk
factors such as obesity. In order to better understand the
relationship, it is important to consider levels of insulin, glucose,
and other diabetes related biomarkers such as adiponectin. Also, it
is pertinent to understand duration of disease and disease
management as these factors may also impact diabetes and/or
cancer prognosis and outcome [78–80]. In addition to pre-existing
DM and associated DM comorbidities, other influences on HCC
prognosis and HCC treatment response may also include the
treatment and management of DM itself. Diabetic treatments may
influence HCC prognosis by creating an environment of
hyperinsulinemia. One study found insulin therapy for diabetic
patients with advanced HCC resulted in a higher recurrence after
hepatic resection [59]. Similarly, sulfonylurea agents provide
glycemic control but also create an environment of hyperinsulin-
emia [93]. Thus, high insulin, rather than high glucose, may be an
important contributing factor of HCC progression and impact
how cells respond to HCC treatment [94].
The key strength of our meta-analysis is that our results were
based on cohort studies, thus ensuring that DM diagnosis
preceded the hepatocellular carcinoma and have less recall bias
due to its prospective nature. Nonetheless, some limitations should
be mentioned. First, substantial heterogeneity was found across the
component studies. This was partly because of different study
areas, study designs, statistical adjustments and methods of
diabetes and outcome assessment in each study according to
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subgroups, indicating that other factors may explain this
heterogeneity. Second, publication bias was detected in the
meta-analysis of all-cause mortality, however, the adjusted
estimate based on trim and fill method had a slightly decrease
and could not reverse the significant positive association, and no
publication bias was found in other parts.
Implications and conclusions
In this meta-analysis, we found an increased risk of HCC in
patients with diabetes mellitus. This finding underscores the need
for preventative measures of diabetes management including
weight control, promotion of measures to increase physical
activity, and maintenance of a healthy diet. We also found that
pre-existing DM is associated with adverse outcomes in hepato-
cellular carcinoma throughout its entire proceeding, from
occurrence, progression, and to mortality. While the mechanism
underlying the association between DM and prognosis remains
unclear, it is important to monitor patients for post-operative
recurrence, post-operative complications and hepatic decomposi-
tion.
Future studies should therefore 1) investigate how preexisting
diabetes influences clinical decisions and how patients with DM
diagnosed with HCC respond to varying treatment modalities for
the latter; 2) determine the role of DM treatment in response to
HCC treatment and prognosis, and 3) clarify the pathophysiology
underlying liver cancer prognosis and diabetes. In addition, the
effect of treatments and duration of diabetes should be taken into
account in future etiological research.
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